Adiponectin and protection against type 2 diabetes mellitus

详细信息    查看全文

• 作者：Spranger ; Joachim ; Kroke ; Anja ; Mö ; hlig ; Matthias ; Bergmann ; Manuela M ; Ristow ; Michael ; et. al.
• 刊名：The Lancet
• 出版年：2003
• 出版时间：January 18, 2003
• 年：2003
• 卷：361
• 期：9353
• 页码：226-228
• 全文大小：72.3 K

文摘

Adiponectin is an adipocyte-derived peptide, which has anti-inflammatory and insulin-sensitising properties. We designed a nested case-control study to assess whether baseline adiponectin concentrations in plasma are independently associated with risk of type 2 diabetes. We found that adiponectin concentrations in plasma were lower among individuals who later developed type 2 diabetes than among controls (mean 5·34 μg/mL [SD 3·49] vs 6·87 μg/mL [4·58], p<0·0001). High concentrations of adiponectin were associated with a substantially reduced relative risk of type 2 diabetes after adjustment for age, sex, waist-to-hip ratio, body-mass index, smoking, exercise, alcohol consumption, education, and glycosylated haemoglobin A_1c (odds ratio 4th vs 1st quartile 0·3 [95 % CI 0·2–0·7], p=0·0051). We conclude that adiponectin is independently associated with a reduced risk of type 2 diabetes in apparently healthy individuals.